Medacta announced the November 2, 2018 acquisition of Balgrist Computer Assisted Research and Development (CARD). The parties did not disclose a purchase price.
Balgrist is a spin-off of Balgrist University Hospital in Zurich, which specializes in the diagnosis, treatment and aftercare of damage to the musculoskeletal system.
With the acquisition, Medacta gains access to a proprietary solution for planning and executing complex osteotomy with a patient-specific approach. To further their commitment in this area, Medacta also announced a four-year partnership in personalized medicine with Balgrist University Hospital to explore unmet clinical needs in orthopaedics.
The acquisition and partnership could position Medacta well amongst its total joint and spine competitors, as personalized medicine becomes increasingly important and companies of all sizes develop patient-specific products and enabling technologies.
We estimated Medacta’s 2017 revenue at $278.1MM, + 11.9% vs. 2018 and ranked the company as a top ten player in knees and hip in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT®.
Medacta announced the November 2, 2018 acquisition of Balgrist Computer Assisted Research and Development (CARD). The parties did not disclose a purchase price.
Balgrist is a spin-off of Balgrist University Hospital in Zurich, which specializes in the diagnosis, treatment and aftercare of damage to the musculoskeletal system.
With the...
Medacta announced the November 2, 2018 acquisition of Balgrist Computer Assisted Research and Development (CARD). The parties did not disclose a purchase price.
Balgrist is a spin-off of Balgrist University Hospital in Zurich, which specializes in the diagnosis, treatment and aftercare of damage to the musculoskeletal system.
With the acquisition, Medacta gains access to a proprietary solution for planning and executing complex osteotomy with a patient-specific approach. To further their commitment in this area, Medacta also announced a four-year partnership in personalized medicine with Balgrist University Hospital to explore unmet clinical needs in orthopaedics.
The acquisition and partnership could position Medacta well amongst its total joint and spine competitors, as personalized medicine becomes increasingly important and companies of all sizes develop patient-specific products and enabling technologies.
We estimated Medacta’s 2017 revenue at $278.1MM, + 11.9% vs. 2018 and ranked the company as a top ten player in knees and hip in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT®.
Copy to clipboard 
